Journal of Pharmacy Technology最新文献

{"title":"Development of a Formal Training Program for Pharmacy Technicians to Assist in a Pediatric Medical Emergency Response.","authors":"Lisa Garavaglia, Erin Atkins","doi":"10.1177/87551225261495834","DOIUrl":"10.1177/87551225261495834","url":null,"abstract":"<p><p>The development and evaluation of a formal training program designed to prepare pharmacy technicians to assist pharmacists during pediatric medical emergency responses is described. A structured training program was implemented at a pediatric hospital including didactic instruction, hands-on training, and a required return demonstration. Training emphasized medication preparation, labeling, automated dispensing system use, identification of emergency medications, and preparation of weight-based pediatric doses. Post-training survey results demonstrated improvements across all measured domains. Implementation of a formal pharmacy technician training program improved technician confidence in emergency response medications while supporting effective performance during pediatric medical emergencies.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261495834"},"PeriodicalIF":1.5,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13676681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lecanemab-Monoclonal Antibodies for the Treatment of Early Alzheimer's Disease.","authors":"Jasmine Cutler, Bao Anh Tran, Krystal Bullers, Carol Fox","doi":"10.1177/87551225261492568","DOIUrl":"10.1177/87551225261492568","url":null,"abstract":"<p><strong>Objective: </strong>Review the pharmacology, efficacy, and safety of lecanemab, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody, for the treatment of early Alzheimer's disease (AD).</p><p><strong>Data sources: </strong>Comprehensive search of Embase, PubMed, International Pharmaceutical Abstracts, Cochrane CENTRAL, Scopus, Web of Science, and Google Scholar were conducted from inception through December 2025.</p><p><strong>Study selection and data extraction: </strong>Phase I-III clinical trials, systematic reviews, and meta-analyses evaluating lecanemab pharmacology, pharmacokinetics, efficacy, and safety were included. Product labeling was reviewed to supplement clinical data.</p><p><strong>Data synthesis: </strong>In the phase III Clarity AD trial, patients were randomized 1:1 to lecanemab 10 mg/kg every 2 weeks or placebo. The primary endpoint was change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) score at 18 months. Lecanemab demonstrated a mean change of 1.21 versus 1.66 with placebo (difference, -0.45; 95% CI, -0.67 to -0.23; <i>P</i> < .001). Secondary endpoint, amyloid burden via positron emission tomography (PET) scans (<i>n</i> = 698) showed -55.48 centiloids with lecanemab versus 3.64 with placebo (difference -59.12 centiloids; 95% CI, -62.64 to -55.6; <i>P</i> < .001). Additional endpoints included changes in ADAS-cog 14, ADCOMS, and ADCS-MCI-ADL scores favoring lecanemab over placebo. Lecanemab was well tolerated; infusion site reactions occurred in 26.4%. Amyloid-related imaging abnormalities (ARIA-E) occurred in 12.6% of participants.</p><p><strong>Conclusion: </strong>Compared to placebo, lecanemab demonstrated statistically significant slowing of cognitive decline on CDR-SB and secondary endpoints, including amyloid burden reduction. However, its clinical benefit must be weighed against ARIA risk and substantial financial burden. Current evidence supports its use in carefully selected patients with early AD under close supervision.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261492568"},"PeriodicalIF":1.5,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13672703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Empiric Linezolid Compared With Vancomycin on Inpatient Outcomes.","authors":"Stacey C Excellent, Jason Hoffmann, Pamela Andrews, Patricia R Louzon","doi":"10.1177/87551225261490026","DOIUrl":"10.1177/87551225261490026","url":null,"abstract":"<p><strong>Background: </strong>Vancomycin and linezolid are commonly used for empiric treatment of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA), but differences may influence the preferred agent. Vancomycin requires individualized dosing and drug monitoring, possibly delaying initiation. Linezolid offers fixed dosing, and potentially lower costs, which may improve time to first dose. This study compares clinical, operational, and cost outcomes associated with empiric vancomycin and linezolid use.</p><p><strong>Methods: </strong>This single-center, retrospective chart review included a convenience sample of 100 hospitalized adults receiving more than 1 dose of empiric vancomycin or linezolid, stratified by level of care (intensive care unit [ICU] vs non-ICU). The primary endpoint was 30-day all-cause mortality. Secondary endpoints included time to first dose, adverse events, therapy changes, treatment duration, length of stay (LOS), cost, and vancomycin dosing characteristics.</p><p><strong>Results: </strong>A convenience sample of 100 patients (50 per group) was analyzed. Thirty-day all-cause mortality was 22% with vancomycin versus 12% with linezolid (<i>P</i> = .183). No statistically significant differences were observed in time to first dose (2.03 ± 1.51 hours vs 1.6 ± 1.66 hours, <i>P</i> = .180). No statistically significant difference was detected in therapy changes, treatment duration, hospital/ICU LOS, treatment failure, and adverse events. Vancomycin had a higher medication cost ($46.59 vs $29.52, <i>P</i> = .012). Patients receiving vancomycin had an average of 2.8 levels, requiring a median of 54.6 hours to reach therapeutic range, maintaining it for 29.5% of treatment duration. This study is limited by its retrospective design and small sample size.</p><p><strong>Conclusion: </strong>No statistically significant differences in clinical outcomes were detected between patients receiving empiric linezolid and vancomycin. Linezolid was associated with lower drug acquisition cost.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261490026"},"PeriodicalIF":1.5,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13661815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149182696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Chromium Picolinate Supplementation and Insulin Requirements in Critically Ill Adults With Type 2 Diabetes Mellitus.","authors":"Alvin Tomika, Corey Finnell, Reesie Yann, Phuoc Tyler Bui","doi":"10.1177/87551225261489120","DOIUrl":"10.1177/87551225261489120","url":null,"abstract":"<p><strong>Background: </strong>Chromium picolinate has been studied as an adjunct to improve glycemic indices in ambulatory type 2 diabetes mellitus, but its role in critically ill patients is unknown.</p><p><strong>Objective: </strong>To evaluate whether chromium picolinate supplementation was associated with reduced insulin requirements without worsening glycemic control in critically ill adults with type 2 diabetes mellitus.</p><p><strong>Methods: </strong>We conducted a single-center retrospective pre-post cohort study of adult intensive care unit patients with type 2 diabetes mellitus or hemoglobin A1c ≥6.5% who received insulin and at least 4 consecutive chromium picolinate doses between July 2022 and January 2023. Patients served as their own controls during 24-hour pre- and post-chromium periods. The primary outcome was change in total daily insulin dose. Secondary outcomes included proportion of measured glucose values within 140 to 180 mg/dL, acute kidney injury, hypoglycemia, and exploratory Sequential Organ Failure Assessment-2 change.</p><p><strong>Results: </strong>Among 91 screened patients, 45 met the inclusion criteria. Median total daily insulin dose decreased from 76.3 U/d (interquartile range [IQR], 40.1-96.9) before chromium to 40.0 U/d (IQR, 20.5-65.6) after chromium; the Hodges-Lehmann paired difference was -23.0 U/d (95% CI, -33.25 to -14.25; <i>P</i> < .0001). Proportion of measured glucose values within target did not differ significantly. No post-intervention hypoglycemia was observed, and 2 patients met the study-defined acute kidney injury criterion. Interpretation is limited by the retrospective design and absence of a concurrent control group.</p><p><strong>Conclusions: </strong>Chromium picolinate supplementation was associated with lower insulin requirements without worsening glycemic control. These hypothesis-generating findings require confirmation in prospective controlled studies.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261489120"},"PeriodicalIF":1.5,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13661817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149182684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal Association Between Aromatase Inhibitor Initiation and New-Onset Atrial Fibrillation: A Case Report.","authors":"Samantha Prevete, Nash Chittem, Katelyn J Galli","doi":"10.1177/87551225261492174","DOIUrl":"https://doi.org/10.1177/87551225261492174","url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer is the most prevalent cancer among women worldwide with a higher probability of diagnosis in the postmenopausal years. Aromatase inhibitors (AIs) block the aromatase enzyme responsible for converting androgens into estrogens in the peripheral tissues, which become the main source for estrogen production in this population. Estrogen plays a key role in promoting vasodilation and inhibiting vascular injury and atherosclerosis development. Reduced levels can contribute to adipocyte hyperplasia, insulin resistance, and dyslipidemia, all of which are risk factors for atrial fibrillation.</p><p><strong>Patient case: </strong>We describe the case of a 71-year-old postmenopausal female who presented to the emergency department with shortness of breath and was subsequently diagnosed with new-onset atrial fibrillation. This case report aims to evaluate whether there is a potential correlation between the initiation of an AI and the development of atrial arrhythmias.</p><p><strong>Discussion: </strong>While existing data suggest an association between AI use and atrial fibrillation, there lacks an elaborate understanding of the temporal relationship between the 2. This case highlights a potential association between AI therapy and unusually rapid-onset atrial fibrillation, demonstrating the need for further research and increased clinical awareness when managing patients receiving these treatments.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261492174"},"PeriodicalIF":1.5,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13652982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149165707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apixaban After Alteplase for Pulmonary Embolism.","authors":"Erik M Wasowski, Mya Beattie","doi":"10.1177/87551225261490396","DOIUrl":"https://doi.org/10.1177/87551225261490396","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary embolism guidelines recommend starting parenteral anticoagulation after completion of thrombolytic therapy for patients who receive thrombolytics; however, there is no guidance on dosing factor Xa inhibitors in this population upon transition to oral anticoagulation. Prior to the Food and Drug Administration approval of direct oral anticoagulants, warfarin was the standard of care, which does not have a standard dose; rather, it has a standard goal international normal range.</p><p><strong>Objective: </strong>The study's aim was to assess the safety and efficacy of apixaban at standard thromboembolic dosing versus alternative dosing after alteplase in patients who received systemic thrombolytic therapy for pulmonary embolism.</p><p><strong>Methods: </strong>This study was approved by the institutional review board and was a retrospective, non-interventional cohort study completed at Cleveland Clinic Ohio Hospitals from January 1, 2018, to October 1, 2025, that analyzed patients who received systemic alteplase for initial management of pulmonary embolism and were transitioned to apixaban prior to discharge.</p><p><strong>Results: </strong>A total of 205 patients received alteplase, with 58 patients meeting the inclusion criteria, including 50 patients receiving standard apixaban dosing and 8 receiving alternative dosing. Bleeding events were similar between groups: 8% versus 13%, <i>P</i> = .538; however, this study was underpowered. Death was more common in the alternative dosing group: standard group was 2% versus 25% in the alternative group; <i>P</i> = .047; however, no deaths were related to anticoagulation adverse events. Limitations to the study include small sample size and a single health system.</p><p><strong>Conclusion: </strong>Patients who received systemic thrombolytic therapy for pulmonary embolism had similar rates of bleeding when using standard apixaban dosing compared with alternative apixaban dosing.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261490396"},"PeriodicalIF":1.5,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13652973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149165638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Readability of National Institutes of Health Patient Education Materials Focused on Mental Health.","authors":"Michelle Pawlowski, Julie Kalabalik-Hoganson, Ayşe Elif Özdener-Poyraz, Malgorzata Slugocki","doi":"10.1177/87551225261487336","DOIUrl":"10.1177/87551225261487336","url":null,"abstract":"<p><strong>Background: </strong>The National Institutes of Health (NIH) recommends patient education materials (PEMs) be written below a seventh-grade reading level. Appropriate reading levels are important, as patients with mental health conditions and low health literacy are at greater risk of poor health outcomes.</p><p><strong>Objective: </strong>To assess and compare the readability level of NIH mental health PEMs using the Readable website and 2 artificial intelligence (AI) chatbots.</p><p><strong>Methods: </strong>Readability metrics (Flesch-Kinkaid reading level, Gunning Fog, Coleman-Liau, SMOG, and Automated Readability Index) of NIH mental health PEMs were evaluated using Readable, ChatGPT, and Claude AI in this cross-sectional descriptive study. Common readability issues were collected. Coloring pages and activity worksheets for children were excluded.</p><p><strong>Results: </strong>Forty PEMs were included in the final analysis. The average Flesch-Kincaid reading levels according to Readable, ChatGPT, and Claude were 8.74 (SD 1.85), 10.44 (SD 3.13), and 9.58 (SD 2.49), respectively. Average Gunning Fog, Coleman-Liau, SMOG, and Automated Readability Index scores provided by Readable were 10.51 (SD 2.09), 14.29 (SD 2.36), 11.27 (SD 1.46), and 10.18 (SD 2.13), respectively. The most common readability issue was sentences exceeding 20 syllables. Limitations included a single-time-point readability assessment of NIH mental health PEMs limited to 2 AI chatbots.</p><p><strong>Conclusion: </strong>NIH mental health PEMs consistently exceeded the seventh-grade reading level and should be revised to adhere to NIH recommendations. Readability metrics varied across Readable and AI chatbot platforms. Improving PEM readability enhances patient understanding, promotes informed decision-making, and reduces disparities linked to limited health literacy, particularly within mental health populations.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261487336"},"PeriodicalIF":1.5,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tradipitant for Motion Sickness: Expanding the Therapeutic Landscape of NK₁ Receptor Antagonists.","authors":"Erin St Onge, Adonice Khoury","doi":"10.1177/87551225261486011","DOIUrl":"10.1177/87551225261486011","url":null,"abstract":"<p><strong>Objective: </strong>To review the efficacy, safety, and tolerability of tradipitant for the prevention of vomiting induced by motion.</p><p><strong>Data sources: </strong>A literature search was conducted through PubMed using the following terms: tradipitant, motion sickness, Nereus, and neurokinin-1 (NK-1) receptor antagonist.</p><p><strong>Study selection and data extraction: </strong>Articles describing the pharmacology, pharmacokinetics, efficacy, safety, and/or tolerability of tradipitant were included in this review.</p><p><strong>Data synthesis: </strong>Tradipitant is a NK-1 receptor antagonist shown to reduce vomiting due to motion. Clinical trials have demonstrated improvements in the occurrence of vomiting as well as multiple episodes of vomiting secondary to various sea conditions. Common adverse effects associated with this agent include fatigue, somnolence, and headache when taken as a single-dose treatment.</p><p><strong>Conclusions: </strong>Scopolamine and first-generation antihistamines are commonly used to prevent and treat motion sickness; however, their use is limited by their significant adverse effect profiles. Tradipitant, the newest agent approved for motion sickness, provides clinicians with an additional treatment option for this common condition.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261486011"},"PeriodicalIF":1.5,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13586080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Emergency Medicine Pharmacist on Door-to-Needle Tenecteplase Time for Acute Ischemic Stroke.","authors":"Brittany Bata, Griffin Calme, Kayla Craig, Kaitlyn DeHoff","doi":"10.1177/87551225261486010","DOIUrl":"10.1177/87551225261486010","url":null,"abstract":"<p><p><b>Background:</b> Emergency medicine pharmacist (EMP) involvement in stroke care has been associated with shorter door-to-needle (DTN) times of alteplase administration, which is crucial for optimizing outcomes in patients with acute ischemic stroke (AIS). Tenecteplase (TNK) is an alternative thrombolytic treatment, recently approved for AIS. The impact of EMP presence with use of TNK for AIS is unknown. <b>Objective:</b> To evaluate the effect of EMP presence on DTN times with TNK administration in patients with AIS. <b>Methods:</b> This single-center, retrospective cohort study evaluated adult patients who received TNK for AIS in the emergency department between January 1, 2023 and December 31, 2025. Patients were divided into 2 groups based on the presence or absence of an EMP. The primary outcome measured median DTN time. <b>Results:</b> Of the 154 included patients, 98 patients had an EMP involved in their stroke care. EMP presence was associated with a shorter median DTN time: 45 versus 56.5 minutes in the EMP absent group (<i>P</i> = .004). Emergency medicine pharmacist presence had faster median TNK preparation times (3 vs 9.5 minutes; <i>P</i> < .001) and faster administration times following preparation (4 vs 8 minutes; <i>P</i> < .001). National Institutes of Health Stroke Scale at 24 hours, intracranial hemorrhage, length of stay, and in-hospital mortality did not differ between groups. <b>Conclusion:</b> An EMP at the bedside of patients presenting with AIS resulted in reduced DTN time with TNK administration. These findings support the role of bedside pharmacists in stroke response teams to improve efficiency and achieve time-sensitive treatment goals.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261486010"},"PeriodicalIF":1.5,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13562442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148956056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of <i>Clostridioides difficile</i> Infection in Patients Treated With a Partial Versus Complete Course of Fidaxomicin.","authors":"Caroline Rosario, Ethan Rausch, Rohit Soman, Kaitlin Beckman, Jordan Smith, Amanda Lefemine","doi":"10.1177/87551225261479991","DOIUrl":"10.1177/87551225261479991","url":null,"abstract":"<p><strong>Background: </strong>High cost and inconsistent insurance coverages may necessitate partial completion of a fidaxomicin course with an alternative antibiotic.</p><p><strong>Objective: </strong>This study aimed to evaluate the impact of a partial versus complete course of fidaxomicin on <i>Clostridioides difficile</i> infection (CDI) treatment outcomes.</p><p><strong>Methods: </strong>This was a retrospective, multicenter cohort study of adult hospitalized patients with CDI treated with fidaxomicin from May 2022 through August 2023. Patients treated with a complete fidaxomicin course (≥20 doses) were compared with those treated with a partial fidaxomicin course (<20 doses). The primary outcome was 90-day CDI recurrence. Secondary outcomes were 30-day CDI recurrence, 90-day hospital readmissions, 90-day all-cause mortality, and hospital length of stay.</p><p><strong>Results: </strong>The study included 39 patients in the complete fidaxomicin and 11 patients in the partial fidaxomicin group. The partial fidaxomicin group observed a numerically higher rate of 90-day recurrence (12.8% vs 18.2%; <i>P</i> = .641). Similar patterns were observed for all secondary outcomes, except length of stay, which was longer in the complete fidaxomicin group (23.9 vs 9.8 days; <i>P</i> = .301). Among patients who completed treatment after discharge (62%), a gap in therapy of greater than 4 days was more frequent in the complete fidaxomicin group (2/22 vs 0/9; <i>P</i> = 1.000).</p><p><strong>Conclusions: </strong>Partial completion of a fidaxomicin course with an alternative antibiotic was associated with a numerically higher rate of CDI recurrence, readmission, and all-cause mortality. Small sample size limited the ability to detect statistically significant differences in these findings. Larger comparative effectiveness studies are needed.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261479991"},"PeriodicalIF":1.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148930180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}